GET DAILY SIGNALSWhy Is Amgen Inc. (AMGN) Stock Down -7.28% Today?
Key Takeaways
- AMGN shares fell roughly 7.28% (about $31.81) to approximately $405.42 in Tuesday trading.
- The primary catalyst was a failed late-stage trial from rival Novartis, which rattled confidence in the entire Lp(a)-lowering drug class, including Amgen's experimental olpasiran.
- A valuation-driven downgrade from BMO Capital Markets to Market Perform added to the selling pressure.
- Broader market weakness, including a lower Dow and surging oil prices on U.S.–Iran tensions, compounded the decline.
- Traders are now focused on results from Amgen's own OCEAN(a)-Outcomes study as the next major catalyst.
Opening Summary
Amgen Inc. (AMGN), the Thousand Oaks, California-based biotechnology giant behind blockbuster therapies such as Repatha, Prolia, and Enbrel, saw its shares tumble in Tuesday's session. The stock fell about 7.28%, or $31.81, to roughly $405.42, down from a prior closing price of $437.23. The move was driven primarily by a failed late-stage cardiovascular trial from rival Novartis that cast a shadow over Amgen's own experimental cholesterol drug, compounded by a valuation-driven analyst downgrade and a softer overall market.
Novartis Trial Failure Hits the Lp(a) Drug Class
The dominant catalyst behind the selloff was Novartis' disclosure that pelacarsen, its experimental treatment designed to sharply lower lipoprotein(a), or Lp(a), failed to meet its primary endpoint in the pivotal Lp(a)HORIZON Phase 3 trial. Despite successfully reducing Lp(a) levels in treated patients, the drug did not lower the risk of cardiovascular death, heart attack, or stroke compared with placebo.
The result matters enormously for Amgen because the company is developing olpasiran, an investigational siRNA therapy designed to suppress Lp(a) production in the liver, currently being evaluated in the Phase 3 OCEAN(a)-Outcomes study. While olpasiran uses a different drug design and may target a different patient population, the Novartis miss undermined a core assumption underpinning the entire therapeutic class: that dramatically lowering Lp(a) would translate into fewer cardiovascular events. Analysts cautioned that the failure weakens—but does not refute—the scientific rationale, yet investors reassessed the commercial value of the pipeline, pressuring the stock.
Analyst Downgrade Adds to Selling Pressure
The market reaction was amplified by a downgrade from BMO Capital Markets, which cut AMGN to Market Perform from Outperform while maintaining a $450 price target. The firm cited the stock's roughly 34% year-to-date gain, arguing that commercial execution is now largely reflected in the share price, and flagged significant loss-of-exclusivity headwinds across key franchises including Prolia/XGEVA, Enbrel, Otezla, and Kyprolis. BMO also noted that Phase 2 efficacy and tolerability data for the company's obesity candidate MariTide left questions about its competitiveness against established injectable and oral therapies.
Market Context and Trading Activity
The decline unfolded against a backdrop of broader market weakness. The Dow Jones Industrial Average, where AMGN carries one of the highest share prices and therefore outsized influence, fell more sharply than the S&P 500, with Amgen's slide alone accounting for a meaningful portion of the index's decline. Oil prices climbed roughly 3% on escalating U.S.–Iran tensions following the Labor Day weekend, adding a risk-off tone to the session.
The move pulled the stock well below its 52-week high of $447.03, which it had approached only weeks earlier. Trading activity was notably heavy as investors repositioned across the cardiovascular and broader biotech complex, with other Lp(a)-focused names such as NewAmsterdam Pharma also coming under pressure.
What Comes Next for AMGN
Investor attention now turns to Amgen's own OCEAN(a)-Outcomes study, which has completed enrollment of 7,297 participants and is tracking cardiovascular outcomes over roughly five years. JPMorgan analysts noted that the Novartis result lowers expectations for olpasiran ahead of late-stage data anticipated in late 2027 or early 2028, and expressed skepticism about whether the drug's effect would prove clinically meaningful enough to support a significant commercial opportunity.
Beyond the pipeline, traders will monitor the durability of Amgen's core franchise revenues amid patent expirations, progress on the MariTide obesity program, and any further analyst or regulatory developments. The stock's elevated valuation relative to the broader pharmaceutical sector also leaves it vulnerable to additional volatility should clinical or commercial expectations shift.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots designed to navigate shifting market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. To discover which automated strategies are leading right now, visit the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 46 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.132) is normal, around the industry mean (-1.235). P/E Ratio (29.499) is within average values for comparable stocks, (21.492). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement